Rchr

J-GLOBAL ID：200901023615812232 Update date: Sep. 01, 2020

Masato Umikawa

ウミカワマサト | Masato Umikawa

Affiliation and department：
Job title： Associate Professor

Research field (2)： Molecular biology , Cell biology

Research keywords (2)：実験遺伝学 , 生化学

Papers (14)：

Tessho Maruyama, Kazuhide Nishihara, Masato Umikawa, Akira Arasaki, Toshiyuki Nakasone, Fumikazu Nimura, Akira Matayoshi, Kimiko Takei, Saori Nakachi, Ken-Ichi Kariya, et al. MicroRNA-196a-5p is a potential prognostic marker of delayed lymph node metastasis in early-stage tongue squamous cell carcinoma. Oncology Letters. 2018. 15. 2. 2349-2363
Masato Umikawa, Asako Umikawa, Tsuyoshi Asato, Kimiko Takei, Goro Matsuzaki, Ken-ichi Kariya, Cheng Cheng Zhang. Angiopoietin-like protein 2 induces proinflammatory responses in peritoneal cells. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2015. 467. 2. 235-241
Junke Zheng, Masato Umikawa, Changhao Cui, Jiyuan Li, Xiaoli Chen, Chaozheng Zhang, HoangDinh Hyunh, Xunlei Kang, Robert Silvany, Xuan Wan, et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. NATURE. 2012. 485. 7400. 656-+
HoangDinh Huynh, Junke Zheng, Masato Umikawa, Chaozheng Zhang, Robert Silvany, Satoru Iizuka, Martin Holzenberger, Wei Zhang, Cheng Cheng Zhang. IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells. BLOOD. 2011. 118. 12. 3236-3243
Junke Zheng, Masato Umikawa, Shichuan Zhang, HoangDinh Huynh, Robert Silvany, Benjamin P. C. Chen, Lieping Chen, Cheng Cheng Zhang. Ex Vivo Expanded Hematopoietic Stem Cells Overcome the MHC Barrier in Allogeneic Transplantation. CELL STEM CELL. 2011. 9. 2. 119-130

ｍore...

MISC (18)：

ｍore...

Professional career (1)：

- (Osaka University)

Work history (2)：

2002/07/16 - - , 琉球大学医学研究科医科学専攻准教授
2002/07/16 - - , University of the Ryukyus, Graduate School of Medicine, Graduate School of Medical Science, Associate Professor

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM